natgillin/translations-raw huggingface dataset:
Very common: Decreased total bilirubin, increased GGT, elevated plasma prolactin levels 16 
Zelo pogosti: Nizek celokupni bilirubin, visok GGT, zvišane plazemske koncentracije prolaktina16
You should take your Olanzapine Glenmark tablets once a day following the advice of your doctor. 
Olanzapine Glenmark tablete jemljite enkrat na dan, in sicer upoštevajte nasvet zdravnika.
It is important that you carry on taking Olanzapine Glenmark for as long as your doctor tells you. 
Pomembno je, da nadaljujete z jemanjem zdravila Olanzapine Glenmark tako dolgo, kot vam naroči zdravnik.
Discontinuation symptoms7, 12 
dtegnitveni simptomi7, 12
- Tell your doctor if you or someone else in your family has a history of blood clots, as medicines like these have been associated with the formation of blood clots. 
• Če ste vi ali kdo iz vaše družine v preteklosti imeli krvne strdke, morate o tem obvestiti svojega zdravnika, saj lahko zdravila, kot je to, povzročijo nastanek krvnih strdkov.
Long-term olanzapine treatment (up to 12 months) for recurrence prevention in patients with bipolar disorder was associated with an increase of ≥ 7 % from baseline body weight in 39.9 % of patients. 
Dolgoročno zdravljenje z olanzapinom (do 12 mesecev) za preprečevanje ponovnega pojava bolezni pri bolnikih z bipolarno motnjo je bilo povezano s povečanjem telesne mase za ≥ 7 % z osnove pri 39,9 % bolnikov.
The plasma protein binding of Olanzapine was about 93 % over the concentration range of about 7 to about 1000 ng/ml. 
Vezava olanzapina na plazemske beljakovine je bila okoli 93 % v razponu koncentracij od približno 7 do približno 1000 ng/ml.
However the risk of tardive dyskinesia increases with long-term exposure, and therefore if signs or symptoms of tardive dyskinesia appear in a patient on olanzapine, a dose reduction or discontinuation should be considered. 
Vendar pa tveganje za tardivne diskinezije narašča s trajanjem zdravljenja in je zato ob pojavu znakov ali simptomov tardivnih diskinezij pri bolniku, ki prejema olanzapin, treba razmisliti o znižanju odmerka ali ukinitvi zdravila.
Effects on haematology parameters were found in each species, including dose-related reductions in circulating leukocytes in mice and non-specific reductions of circulating leukocytes in rats; however, no evidence of bone marrow cytotoxicity was found. 
Pri vsaki vrsti so odkrili učinke na hematološke parametre, vključno z odmerkom povezanimi znižanji koncentracij levkocitov v obtoku pri miših in nespecifičnim znižanjem koncentracije levkocitov v obtoku pri podganah; vendar pa niso našli dokazov citotoksičnosti za kostni mozeg.
If this happens, contact your doctor at once. 
Če se zgodi kaj takega, se nemudoma obrnite na svojega zdravnika.
Consult your doctor if your symptoms return but do not stop taking Olanzapine Glenmark unless your doctor tells you to. 
Če se simptomi povrnejo, se posvetujte s svojim zdravnikom, vendar ne prenehajte jemati zdravila Olanzapine Glenmark, če vam tega ne naroči vaš zdravnik.
What Olanzapine Glenmark is and what it is used for What you need to know before you take Olanzapine Glenmark How to take Olanzapine Glenmark Possible side effects 
Kaj je zdravilo Olanzapin Glenmark in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Olanzapin Glenmark Kako jemati zdravilo Olanzapin Glenmark Možni neželeni učinki
DRESS appears initially as flu-like symptoms with a rash on the face and then with an extended rash, high temperature, enlarged lymph nodes, increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell (eosinophilia). 
Sindrom DRESS se sprva kaže kot gripi podobni simptomi z izpuščajem na obrazu, nato pa z razširjenim izpuščajem, visoko telesno temperaturo, povečanimi bezgavkami, povišanimi ravnmi jetrnih encimov na izvidih krvnih testov in s povišanjem vrste belih krvničk (eozinofilija).
The frequency terms listed are defined as follows: Very common (≥ 1/10), common (≥ 1/100 to < 
Našteti izrazi pogostnosti so definirani kot sledi: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10).
The frequency terms listed are defined as follows: Very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the data available). 
Našteti izrazi pogostnosti so definirani kot sledi: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000), ni znano (ocena ni možna iz danih podatkov).
Cytochromes P450-CYP1A2 and P450-CYP2D6 contribute to the formation of the N-desmethyl and 2-hydroxymethyl metabolites, both exhibited significantly less in vivo pharmacological activity than olanzapine in animal studies. 
Citokroma P450-CYP1A2 in P450CYP2D6 prispevata k tvorbi N-demetilnih in 2-hidroksimetilnih metabolitov, oboji so v študijah na živalih pokazali pomembno manj farmakološke aktivnosti in vivo kot olanzapin.
Date of latest renewal: 19 August 2014 
Datum zadnjega podaljšanja dovoljenja za promet: 19 Avgust 2014
Olanzapine is bound predominantly to albumin and α1-acid-glycoprotein. 
Olanzapin se veže predvsem na albumin in 1-kisli glikoprotein.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in pretisnem omotu poleg oznake »Uporabno do«.
Olanzapine should be used cautiously in patients who have a history of seizures or are subject to factors, which may lower the seizure threshold. 
Olanzapin je treba uporabljati previdno pri bolnikih, ki so imeli v preteklosti epileptične napade ali so podvrženi dejavnikom, ki bi lahko znižali prag za epileptične napade.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 03 December 2009 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum pridobitve dovoljenja za promet: 03 December 2009
In addition, a Single Photon Emission Computed Tomography (SPECT) imaging study in schizophrenic patients revealed that olanzapine-responsive patients had lower striatal D2 occupancy than some other antipsychotic and risperidone-responsive patients, while being comparable to clozapine-responsive patients. 
Dodatno je SPECT (Single Photon Emission Computed Tomography) slikovna študija pri bolnikih s shizofrenijo razkrila, da so imeli bolniki, ki so se odzivali na olanzapin, nižjo zasedenost striatnih D2 receptorjev kot bolniki, ki so se odzivali na nekatere druge antipsihotike in risperidon, medtem ko je bila primerljiva z bolniki, ki so se odzivali na klozapin.
This may be harmful for people with phenylketonuria. 
Lahko škoduje ljudem s fenilketonurijo.
2 Mean increases in fasting lipid values (total cholesterol, LDL cholesterol, and triglycerides) were greater in patients without evidence of lipid dysregulation at baseline. 
2Povprečna povišanja vrednosti lipidov na tešče (celokupni holesterol, LDL holesterol in trigliceridi) so bila večja pri bolnikih brez očitne slabe regulacije lipidov na osnovi.
The most frequently (seen in ≥ 1 % of patients) reported adverse reactions associated with the use of olanzapine in clinical trials were somnolence, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels (see section 4.4), glucosuria, increased appetite, dizziness, akathisia, parkinsonism, leukopenia, neutropenia (see section 4.4), dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic elevations of hepatic aminotransferases (see section 4.4), rash, asthenia, fatigue, pyrexia, arthralgia, increased alkaline phosphatase, high gamma glutamyltransferase, high uric acid, high creatine phosphokinase and oedema. 
Najpogosteje poročani (opažene pri  1 % bolnikov) neželeni učinki, povezani z uporabo olanzapina v kliničnih preskušanjih, so bili zaspanost, povečanje telesne mase, eozinofilija, zvišane ravni prolaktina, holesterola, glukoze in trigliceridov (glejte poglavje 4.4), glikozurija, povečan apetit, omotica, akatizija, parkinsonizem, levkopenija, nevtropenija (glejte poglavje 4.4), diskinezija, ortostatska hipotenzija, antiholinergični učinki, prehodna asimptomatska zvišanja jetrnih aminotransferaz (glejte poglavje 4.4), izpuščaj, astenija, utrujenost, pireksija, artralgija, zvišana alkalna fosfataza, visoka raven gama-glutamiltransferaze, visoka raven sečne kisline, visoka raven kreatin-fosfokinaze in edem.
The daily dose of Olanzapine Glenmark is between 5 mg and 20 mg. 
Dnevni odmerek zdravila Olanzapine Glenmark je med 5 mg in 20 mg.
Olanzapine Glenmark tablets are for oral use. 
Olanzapine Glenmark obložene tablete so za peroralno uporabo.
Olanzapine administered with lithium or valproate resulted in increased levels (≥ 10 %) of tremor, dry mouth, increased appetite, and weight gain. 
Olanzapin dan z litijem ali valproatom je povzročil zvišane ravni (≥ 10 %) tresenja, suhih ust, povečanega apetita in povečanja telesne mase.
If you take more Olanzapine Glenmark than you should Patients who have taken more Olanzapine Glenmark than they should have experienced the following symptoms: rapid beating of the heart, agitation/aggressiveness, problems with speech, unusual movements (especially of the face or tongue) and reduced level of consciousness. 
Če ste vzeli večji odmerek zdravila Olanzapine Glenmark, kot bi smeli Bolniki, ki so vzeli večji odmerek zdravila Olanzapine Glenmark, kot bi smeli, so imeli naslednje simptome: hitro bitje srca, vznemirjenost/nasilnost, težave pri govoru, nenavadne zgibke (posebno v mišicah obraza ali jezika) in zmanjšano stopnjo zavesti.
Olanzapine Glenmark tablet contains aspartame, which is a source of phenylalanine. 
Zdravilo Olanzapin Glenmark tablete vsebuje aspartam, ki je vir fenilalanina.
6.4 Special precautions for storage Store below 30C 
6.4 Posebna navodila za shranjevanje Shranjujte pri temperaturi do 30 C.
Store below 30C. 
Shranjujte pri temperaturi do 30 C.
- Very rarely, medicines of this type cause a combination of fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness. 
• Zelo redko tovrstna zdravila povzročijo kombinacijo zvišanja telesne temperature, pospešenega dihanja, znojenja, okorelosti mišic in dremavosti ali zaspanosti.
Patients treated with any antipsychotic medicines, including olanzapine, should be monitored regularly for lipids in accordance with utilised antipsychotic guidelines e.g. at baseline, 12 weeks after starting olanzapine treatment and every 5 years thereafter. 
Bolnike, zdravljene s katerimkoli antipsihotikom, vključno z zdravilom Olanzapine, moramo redno spremljati glede lipidov, v skladu z znanimi priporočili za antipsihotike, npr. na začetku, 12 tednov po začetku jemanja olanzapina in nato vsakih 5 let.
Amenorrhea Breast enlargement Galactorrhea in females 
Amenoreja Povečanje dojk Galaktoreja pri ženskah
Ventricular tachycardia/fibrillation, sudden death (see section 4.4)11 
Prekatna tahikardija/fibril acija, nenadna smrt (glejte poglavje 4.4)11
Olanzapine Glenmark has been shown to prevent recurrence of these symptoms in patients with bipolar disorder whose manic episode has responded to olanzapine treatment. 
Zdravilo Olanzapin Glenmark dokazano preprečuje ponoven pojav teh simptomov pri bolnikih z bipolarno motnjo, pri katerih se je manična epizoda po zdravljenju z olanzapinom izboljšala.
What Olanzapine Glenmark is and what it is used for 
Kaj je zdravilo Olanzapin Glenmark in za kaj ga uporabljamo
6 In clinical trials, the incidence of Parkinsonism and dystonia in olanzapine-treated patients was numerically higher, but not statistically significantly different from placebo. 
6V kliničnih preskušanjih je bila incidenca parkinsonizma in distonije pri bolnikih, zdravljenih z olanzapinom, številčno večja, a se ni statistično značilno razlikovala od placeba.
This includes any possible side effects not listed in this leaflet See section 4. 
Posvetujte se tudi, če opazite katerekoli neželene učinke, ki niso navedeni v tem navodilu Glej točko 4.
70 tablets 
70 tablet
Patients gaining ≥7%, ≥15% and ≥25% of their baseline body weight with long-term exposure (at least 48 weeks) were very common (64.4 %, 31.7 % and 12.3 % respectively). 
Zvečanje osnovne telesne mase za ≥ 7 %, ≥ 15 % in ≥ 25 % se je pri dolgoročni izpostavljenosti bolnikov (vsaj 48 tednov) pojavljalo zelo pogosto (v 64,4 %, 31,7 % in 12,3 %).
What you need to know before you take Olanzapine Glenmark 
Kaj morate vedeti, preden boste vzeli zdravilo Olanzapin Glenmark
New born infants exposed to antipsychotics (including olanzapine) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery. 
Pri novorojenčkih, ki so bili med tretjim trimesečjem nosečnosti izpostavljeni antipsihotikom (vključno z olanzapinom), obstaja tveganje za pojav neželenih učinkov, vključno z ekstrapiramidnimi in/ali odtegnitvenimi simptomi, katerih jakost in čas trajanja po porodu sta lahko različna.
In a single oral dose (10 mg) Positron Emission Tomography (PET) study in healthy volunteers, olanzapine produced a higher 5HT2A than dopamine D2 receptor occupancy. 
V študiji pozitronske emisijske tomografije (PET) s posameznim peroralnim odmerkom (10 mg) pri zdravih prostovoljcih je olanzapin povzročil višjo zasedenost 5-HT2A kot dopaminskih D2 receptorjev.
Seizures where in most cases a history of seizures or risk factors for seizures were reported11 
Epileptični napadi, pri katerih so jih v večini primerov imeli že kdaj prej ali so poročali o dejavnikih tveganja za epileptične napade11
Very common symptoms in overdose (> 10 % incidence) include tachycardia, agitation/ aggressiveness, dysarthria, various extrapyramidal symptoms, and reduced level of consciousness ranging from sedation to coma. 
Zelo pogosti simptomi pri prevelikem odmerjanju (incidenca > 10 %) vključujejo tahikardijo, vznemirjenost/nasilnost, dizartrijo, različne ekstrapiramidne simptome in motnje zavesti v razponu od sedacije do kome.
• Medicines for Parkinson's disease 
• zdravila za Parkinsonovo bolezen,
Do not stop taking your tablets just because you feel better. 
Če ste prenehali jemati zdravilo Olanzapine Glenmark Ne prenehajte jemati tablet samo zato, ker se počutite bolje.
- The use of Olanzapine Glenmark in elderly patients with dementia is not recommended as it may have serious side effects. 
• Uporaba zdravila OLANZAPINE ni priporočljiva pri starejših bolnikih z demenco, saj lahko povzroči resne neželene učinke.
Development or exacerbation of diabetes occasionally associated with ketoacidosis or coma, including some fatal cases (see section 4.4) 11 
Razvoj ali poslabšanje sladkorne bolezni, občasno povezane s ketoacidozo ali komo, vključno z nekaj smrtnimi primeri (glejte poglavje 4.4)11
If this happens after you have been given Olanzapine Glenmark tell your doctor. 
Če se vam to zgodi po tem, ko ste prejeli zdravilo OLANZAPINE , povejte svojemu zdravniku.
During treatment with olanzapine in combination with lithium or divalproex, an increase of ≥ 7 % from baseline body weight occurred in 17.4 % of patients during acute treatment (up to 6 weeks). 
Med zdravljenjem z olanzapinom v kombinaciji z litijem ali divalproeksom se je pri 17,4 % bolnikov med akutnim zdravljenjem ( do 6 tednov) pojavilo povečanje telesne mase za > 7 % od osnovne.
You should swallow the Olanzapine Glenmark tablets whole, with water. 
Olanzapine Glenmark tablete pogoltnite cele z vodo.
Patients treated with any antipsychotic medicines, including olanzapine, should be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia, and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control. 
Bolnike, zdravljene s katerimkoli antipsihotikom, vključno z zdravilom Olanzapine, moramo opazovati za znake in simptome hiperglikemije (kot so polidipsija, poliurija, polifagija in šibkost) ter redno spremljati bolnike s sladkorno boleznijo ali dejavniki tveganja za sladkorno bolezen glede poslabšanja nadzora glukoze.
In a multinational, double-blind, comparative study of schizophrenia, schizoaffective, and related disorders which included 1,481 patients with varying degrees of associated depressive symptoms (baseline mean of 16.6 on the Montgomery-Asberg Depression Rating Scale), a prospective secondary analysis of baseline to endpoint mood score change demonstrated a statistically significant improvement (p= 0.001) favouring olanzapine (- 6.0) versus haloperidol (- 3.1). 
V dvojno slepi primerjalni študiji shizofrenije, shizoafektivnih in sorodnih motenj, v kateri je sodelovalo več držav in je vključevala 1481 bolnikov z različnimi stopnjami pridruženih depresivnih simptomov (izhodiščna srednja vrednost 16,6 na Montgomery-Asbergovi lestvici ocenjevanja depresije), je prospektivna sekundarna analiza spremembe od izhodiščne do končne ocene razpoloženja pokazala statistično značilno izboljšanje (p = 0,001) v korist olanzapina (-6,0) v primerjavi s haloperidolom (-3,1).
There was a 3-fold increase in CVAE in patients treated with olanzapine compared to patients treated with placebo (1.3 % versus 0.4 %, respectively). 
Pri bolnikih, zdravljenih z olanzapinom, je bila 3-krat večja pojavnost CVAE v primerjavi z bolniki, ki so prejemali placebo (1,3 % v primerjavi z 0,4 %).
In a second 12-month recurrence prevention study in manic episode patients who achieved remission with a combination of olanzapine and lithium and were then randomised to olanzapine or lithium alone, olanzapine was statistically non-inferior to lithium on the primary endpoint of bipolar recurrence (olanzapine 30.0 %, lithium 38.3 %; p = 0.055). 
V drugi 12-mesečni študiji preprečevanja ponovitve bolezni pri bolnikih z manično epizodo, ki so z zdravljenjem s kombinacijo olanzapina in litija dosegli remisijo in so jim nato naključno dodelili prejemanje samo olanzapina ali samo litija, ni bil olanzapin statistično značilno nič slabši kot litij ob primarni končni točki ponovitve bipolarne motnje (olanzapin 30,0 %, litij 38,3 %; p = 0,055).
PHARMACEUTICAL FORM AND CONTENTS 
FARMACEVTSKA OBLIKA IN VSEBINA tableta
- The other ingredients are mannitol (E 421), microcrystalline cellulose, aspartame (E 951), crospovidone, magnesium stearate 
Pomožne snovi so manitol (E 421), mikrokristalna celuloza, aspartam (E 951), krospovidon, magnezijev stearat.
Date of first authorisation: 03 December 2009 Date of latest renewal: 19 August 2014 
Datum pridobitve dovoljenja za promet: 03 December 2009 Datum zadnjega podaljšanja dovoljenja za promet: 19 Avgust 2014
Olanzapine Glenmark belongs to a group of medicines called antipsychotics. 
Zdravilo Olanzapin Glenmark spada v skupino zdravil, imenovanih antipsihotiki in se uporablja za zdravljenje naslednjih bolezni:
Very common: Weight gain 13, elevated triglyceride levels 14, increased appetite. 
Zelo pogosti: Povečanje telesne mase13, zvišane ravni trigliceridov14, povečan apetit Pogosti: Zvišane ravni holesterola15
Olanzapine Glenmark 20 mg tablets are available in aluminium foil blisters of 28, 35, 56, 70 and 98 tablets 
Olanzapin Glenmark 20 mg tablete so na voljo v aluminijastih pretisnih omotih po 28, 35, 56, 70 in 98 tablet.
Parkinsonism6 Dyskinesia6 
Parkinsonizem6 Diskinezije6
The following symptoms may occur in newborn babies, of mothers that have used Olanzapine Glenmark in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding. 
Pri novorojenčkih mater, ki so v zadnjih treh mesecih nosečnosti uporabljale zdravilo Olanzapine Glenmark, se lahko pojavijo naslednji simptomi: tresenje, okornost ali šibkost mišic, zaspanost, nemir, težave z dihanjem in motnje hranjenja.
Olanzapine Glenmark 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg are available in aluminium foil blisters of 28, 56, 70 and 98tablets 
Olanzapin Glenmark 2,5 mg, 5 mg, 7,5 mg, 10 mg, 15 mg tablete so na voljo v aluminijastih pretisnih omotih po 28, 56, 70 in 98 tablet.
How to store Olanzapine Glenmark Contents of the pack and other information 
Shranjevanje zdravila Olanzapin Glenmark Vsebina pakiranja in dodatne informacije
Blood and the lymphatic system disorders 
Bolezni krvi in limfatičnega sistema Eozinofilija
- If you have any further questions, ask your doctor or pharmacist. 
Če imate dodatna vprašanja, se posvetujte z zdravnikom ali s farmacevtom.
If you suddenly stop taking Olanzapine Glenmark, symptoms such as sweating, unable to sleep, tremor, anxiety or nausea and vomiting might occur. 
Če nenadno prenehate jemati zdravilo Olanzapine Glenmark, se lahko pojavijo simptomi, kot so znojenje, nespečnost, tresenje, občutek tesnobe ali slabost in bruhanje.
• Serious allergic reactions such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). 
Zelo redki neželeni učinki vključujejo resne alergijske reakcije, kot je npr. reakcija na zdravilo z eozinofilijo in sistemskimi simptomi (DRESS).
A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE 
A. IZDELOVALCI ZDRAVILA, ODGOVORNI ZA SPROŠČANJE SERIJE
Olanzapine demonstrated a greater in vitro affinity for serotonin 5HT2 than dopamine D2 receptors and greater 5 HT2 than D2 activity in vivo, models. 
V pogojih in vitro je olanzapin pokazal večjo afiniteto za serotoninske 5-HT2 kot za dopaminske D2 receptorje in večjo 5-HT2 kot D2 aktivnost v modelih in vivo.
• Liver or kidney disease 
• obolenje jeter ali ledvic bolezni krvi
Abdominal distension9 
Trebušna distenzija9
Do not drink any alcohol if you have been given Olanzapine Glenmark as together with alcohol it may make you feel drowsy. 
Jemanje zdravila Olanzapine Glenmark skupaj z alkoholom Če ste dobili zdravilo Olanzapine Glenmark, ne pijte nobenega alkohola, saj lahko zdravilo Olanzapine Glenmark in alkohol skupaj povzročita občutek zaspanosti.
Gastrointestinal disorders Mild, transient anticholinergic effects including constipation and dry mouth 
Blagi prehodni antiholinergični učinki, vključno z zaprtjem in suhimi usti
Estrous cycles were affected at doses of 1.1 mg/kg (3 times the maximum human dose) and reproduction parameters were influenced in rats given 3 mg/kg (9 times the maximum human dose). 
3 mg/kg (9-kratni maksimalni odmerek za človeka) pa so pri podganah vplivali na parametre reprodukcije.
Dizziness Akathisia6 
Omotica Akatizija6
In placebo-controlled clinical trials (6-12 weeks duration) of elderly patients (mean age 78 years) with dementia-related psychosis and/or disturbed behaviours, there was a 2-fold increase in the incidence of death in olanzapine-treated patients compared to patients treated with placebo (3.5 % vs 1.5 %, respectively). 
V kliničnih preskušanjih, kontroliranih s placebom (ki so trajali 6-12 tednov), pri starejših bolnikih s psihozo, povezano z demenco in/ali vedenjskimi motnjami (povprečna starost 78 let), je bilo 2-kratno povečanje incidence smrti pri bolnikih, zdravljenih z olanzapinom, v primerjavi z bolniki, zdravljenimi s placebom (3,5 % v primerjavi z 1,5 %).
Following short term treatment (median duration 47 days), weight gain ≥ 7 % of baseline body weight was very common (22.2%), ≥ 15% was common (4.2%) and ≥25% was uncommon (0.8%). 
S kratkoročnim zdravljenjem (srednje trajanje 47 dni) povezano zvečanje telesne mase za ≥ 7 % od osnovne telesne mase je bilo zelo pogosto (22,2 %), ≥ 15 % pogosto (4,2 %) in ≥ 25 % občasno (0,8 %).
There is a risk of feeling drowsy when you are given Olanzapine Glenmark. 
Obstaja tveganje, da se boste po tem, ko ste dobili zdravilo Olanzapine Glenmark, počutili zaspane.
8 In clinical trials of up to 12 weeks, plasma prolactin concentrations exceeded the upper limit of normal range in approximately 30% of olanzapine treated patients with normal baseline prolactin value. 
8V kliničnih preskušanjih, ki so trajala do 12 tednov, so pri 30 % bolnikov z normalno začetno vrednostjo prolaktina, ki so se zdravili z olanzapinom, ugotovili zvišanje plazemske koncentracije prolaktina nad zgornjo mejo normalne vrednosti.